Drug Profile
Research programme: anti-angiogenesis peptides - Affymax/EntreMed
Latest Information Update: 27 Aug 2009
Price :
$50
*
At a glance
- Originator Affymax; EntreMed
- Class Peptides
- Mechanism of Action Angiogenesis inhibitors; VLDL receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Dec 2008 Preclinical development is ongoing in USA
- 16 Jan 2006 Preclinical trials in Cancer in USA (unspecified route)